Drug Trial Radar · NCT07519070
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Apr 5, 2026
Primary completion
Apr 5, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).
Conditions
- IPF
Interventions
HSK44459Drug
HSK44459 Without IPF background therapy
HSK44459Drug
HSK44459 With Nintedanib
HSK44459Drug
HSK44459 With Pirfenidone
PlaceboDrug
Placebo Without IPF background therapy
PlaceboDrug
Placebo With Nintedanib
PlaceboDrug
Placebo With Pirfenidone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FVC from baseline at Week 52Time frame: Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.